ImmunityBio, Inc. (IBRX)
10.51
+0.60
(+6.05%)
USD |
NASDAQ |
Oct 09, 16:00
10.59
+0.08
(+0.76%)
After-Hours: 20:00
ImmunityBio Free Cash Flow : -288.51M for June 30, 2026
Free Cash Flow Chart
Historical Free Cash Flow Data
| Date | Value |
|---|---|
| June 30, 2026 | -288.51M |
| March 31, 2026 | -299.31M |
| December 31, 2025 | -309.19M |
| September 30, 2025 | -324.79M |
| June 30, 2025 | -356.66M |
| March 31, 2025 | -376.90M |
| December 31, 2024 | -398.12M |
| September 30, 2024 | -434.10M |
| June 30, 2024 | -425.62M |
| March 31, 2024 | -412.85M |
| December 31, 2023 | -397.34M |
| September 30, 2023 | -383.77M |
| June 30, 2023 | -387.23M |
| March 31, 2023 | -406.13M |
| December 31, 2022 | -436.90M |
| September 30, 2022 | -409.28M |
| June 30, 2022 | -393.50M |
| March 31, 2022 | -363.94M |
| December 31, 2021 | -307.98M |
| September 30, 2021 | -249.40M |
| June 30, 2021 | -188.63M |
| March 31, 2021 | -127.90M |
| Date | Value |
|---|---|
| December 31, 2020 | -73.09M |
| September 30, 2020 | -65.20M |
| June 30, 2020 | -62.21M |
| March 31, 2020 | -63.10M |
| December 31, 2019 | -65.54M |
| September 30, 2019 | -66.06M |
| June 30, 2019 | -70.31M |
| March 31, 2019 | -71.25M |
| December 31, 2018 | -76.48M |
| September 30, 2018 | -85.48M |
| June 30, 2018 | -85.09M |
| March 31, 2018 | -89.44M |
| December 31, 2017 | -83.60M |
| September 30, 2017 | -70.63M |
| June 30, 2017 | -63.54M |
| March 31, 2017 | -49.80M |
| December 31, 2016 | -45.15M |
| September 30, 2016 | -44.94M |
| June 30, 2016 | -36.03M |
| March 31, 2016 | -35.48M |
| December 31, 2015 | -27.55M |
Free Cash Flow Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Free Cash Flow Benchmarks
| Moderna, Inc. | -1.244B |
| Sarepta Therapeutics, Inc. | 58.34M |
| Arrowhead Pharmaceuticals, Inc. | -75.11M |
| Oncolytics Biotech, Inc. | -26.53M |
| Sangamo Therapeutics, Inc. | -90.46M |
Free Cash Flow Related Metrics
| Cash from Operations (Quarterly) | -66.49M |
| Cash from Investing (Quarterly) | -107.47M |
| Cash from Financing (Quarterly) | 44.44M |
| Free Cash Flow Per Share (Quarterly) | -0.0667 |
| Free Cash Flow to Equity (Quarterly) | -173.83M |
| Free Cash Flow to Firm (Quarterly) | -38.79M |
| Free Cash Flow Yield | -2.74% |